Multiplatform AI Ecosystem
for Drug Discovery

Receptor.AI develops novel therapeutic molecules and AI technologies that accelerate drug discovery

Receptor.AI integrates physics-informed AI, adaptive molecular optimization, and modality-specific discovery platforms to advance therapeutic candidates across complex target biology.

small molecule platform

Targeting of cryptic and
transient protein pockets

Multiparametric optimization
across 80+ endpoints

Design of novel and IP-free
compounds

peptide platform

Design of orally bioavailable
peptides

De novo generation of
functional binders

Targeting of intracellular
proteins

Biologics & Proximity Platform

Antibody-enabled
therapeutics

Induced proximity
modalities

Targeted biologic
modalities

Receptor.AI – Drug Discovery Operating System

The Drug Discovery OS features dedicated platforms for Peptide, Small Molecule, Biologics & Proximity Inducer design, combining dozens of experimentally validated AI models

Small Molecules Platform

AI drug discovery workflows for different target classes: kinases, GPCRs, ion channels, enzymes, etc.
AI pocket identification and targeting including allosteric, hidden, transient, and cryptic pockets.
Automated SAR analysis with a hybrid intelligence approach; AI binding mode identification.
Multiparametric virtual screening and lead optimization with QuorumMap.
Selectivity optimization against highly similar isoforms and mutants.
The largest set of ADMET endpoints for prediction and optimization with ADMETiQ.

Peptide Platform

De novo binder design based on endogenous ligands, PPI partners, or display hits.
Library of 10K+ non-canonical amino acids, non-peptide blocks, and linkage chemistry for unlimited diversity.
Multiparametric optimization of peptide activity, permeability, and oral availability.
Peptide-to-small-molecule workflow to develop compounds with superior ADMET properties.
Scaffold-agnostic system that supports peptides of any topology and secondary structure.

Biologics & Proximity Platform

Designing various proximity inducers, such as degraders and molecular glues and PPI disruptors.
Enabling antibody-based therapeutics, including bispecifics, immune cell engagers, and antibody-guided scaffolds.
Predicting PPI structures and ternary complexes without known structures and homology templates.
Targeting both natural and induced PPIs, including transient and membrane interactions.
Developing diverse modalities such as small molecules, peptides, antibody-derived formats, or drug conjugates.

Co-development Programs

We are currently engaged in 7 co-development projects progressing from hit discovery to preclinical stage. Addressing the industry’s most challenging targets we continuously refine our platforms, expanding their capabilities to deliver impactful new therapies.

co-dev Program

indication

Target ID &
validation

Early discovery

Lead optimization

IND-enabling

Phase 1

Small molecules

RAI-001

Nephrology

RAI-002

Oncology